115012-24-3

Basic information

• Product Name: Pentanamide, 5-amino-N-phenyl-
• CAS NO: 115012-24-3
• Molecular Formula: C11H16N2O
• Molecular Weight: 192.261
• Mol File: 115012-24-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Pentanamide, 5-amino-N-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanamide, 5-amino-N-phenyl-(115012-24-3)
• EPA Substance Registry System: Pentanamide, 5-amino-N-phenyl-(115012-24-3)

Safety Data

• Hazardous Substances Data: 115012-24-3(Hazardous Substances Data)

Upstream product

• 660-88-8 5-aminopentanoic acid 
• 27219-07-4 5-(N-tert-butyloxycarbonyl)aminopentanoic acid 
• 62-53-3 aniline 
• 34413-03-1 6-Anilino-6-oxohexanoic acid 
• 124-04-9 Adipic acid 
• 115012-31-2 Z-δ-Ava-NH-Phenyl 

Downstream Products

• 651768-00-2 5-(2-bromo-acetylamino)-pentanoic acid phenylamide 
• 824970-18-5 thioacetic acid S-[(4-phenylcarbamoyl-butylcarbamoyl)-methyl] ester 

Relevant articles and documents

Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo

Although gastric cancer has become a major public health problem, oral agents applied in clinics for gastric cancer therapy are scarce. Therefore, to explore new oral chemical entities with high efficiency and low toxicity, 41 o-aminobenzamide derivatives based on the scaffolds of MS-275 and SAHA were designed, synthesized, and evaluated for their anti-gastric cancer abilities in vitro and in vivo. Structure-activity relationships were discussed, leading to the identification of compounds F8 (IC50 = 0.28 μM against HGC-27 cell) and T9 (IC50 = 1.84 μM against HGC-27 cell) with improved cytotoxicity, anti-gastric cancer proliferation potency, induction of cell apoptosis and cell cycle arrest ability, inhibition of cell migration and invasion. What is worth mentioning is that compound F8 was more efficient and less toxic than the positive drug capecitabine in vivo on the HGC-27-xenograft model. Meanwhile, compound F8 exhibited suitable pharmacokinetic properties and less acute toxicity (LD50 > 1000 mg/kg). Besides, western blotting analysis, IHC analysis, differentially expressed proteins analysis and ABPP experiment indicated that compound F8 could modulate molecular pathways involved in apoptosis and cell cycle progression. Consequently, compound F8 is a strong candidate for the development of human gastric cancer therapy.

Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design

In order to find novel non-hydroxamate histone deacetylase (HDAC) inhibitors, we synthesized several suberoylanilide hydroxamic acid (SAHA)-based compounds designed on the basis of the catalytic mechanism of HDACs. Among these compounds, mercaptoacetamide 5b was found to be as potent as SAHA. Kinetic enzyme assays and molecular modeling are also reported. In order to find novel non-hydroxamate histone deacetylase (HDAC) inhibitors, we synthesized several suberoylanilide hydroxamic acid (SAHA)-based compounds designed on the basis of the catalytic mechanism of HDACs. Among these compounds, 5b was found to be as potent as SAHA. Kinetic enzyme assays and molecular modeling suggested that the mercaptoacetamide moiety of 5b interacts with the zinc in the active site of HDACs and removes a water molecule from the reactive site of the deacetylation.